NCT07235501Recruiting
Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogeneic Hematopoietic Cell Transplantation
Source: ClinicalTrials.gov · Last updated 5 Oct 2026
Brief summary (registry, in English)
This study evaluates the factors that contribute to chronic graft-versus-host disease, which is a complication that can occur after allogeneic hematopoietic cell transplantation.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 75 (estimated)
- First submitted
- 10 Nov 2025
- Start date
- 1 Nov 2026
- Primary completion date
- 17 Jan 2030
- Lead sponsor
- City of Hope Medical Center
- Diseases
- Childhood cancers
- NCT number
- NCT07235501
What you commit to
- Study type: Observational
- Planned participants: 75
- From 1 Nov 2026 to the primary completion date, 17 Jan 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \* Women of childbearing potential: Pregnant/nursing
- Individuals with impaired decision-making capacity
- An employee who is under the direct/ indirect supervision of the PI/ a co-investigator/ the study manager
- A direct study team member
Who the study is looking for
- \* BOTH COHORTS:
- Documented written informed consent of the participant and/or parent/guardian.
- Assent from pediatric participants will be documented per institutional policies and practice.
- Patients who have received allogeneic hematopoietic cell transplant (HCT) regardless of donor type, condition regimen, or GVHD prophylaxis.
- Age: ≥ 18 years or ≥ 7 years if 30 kg and above
- Willingness to:
- Provide blood sample(s), stool, saliva, and buccal mucosa,
- If applicable: Permit medical record/ clinical laboratory result review
- COHORT 1:
- Patients who have received allogeneic hematopoietic cell transplant (HCT) regardless of donor type, condition regimen, or GVHD prophylaxis.
- COHORT 2:
- Patients diagnosed with cGVHD at any time-point after allogeneic HCT regardless of donor type, condition regimen, or GVHD prophylaxis.
Age in the registry: 7 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| City of Hope Medical Center Coordinator of this site? Confirm its status | Duarte | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.